{"search_session":{},"preferences":{"l":"fr","queryLanguage":"fr"},"patentId":"171-384-974-364-467","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"171-384-974-364-467","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11848,"type":"PATENT","title":"University of Leipzig Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":11627,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8460,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:univ* AND Leipzig. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1306
Search Applicants and Owners separately:univ* AND Mainz. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1203
Search Applicants and Owners separately:univ* AND Leipzig. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1306
Search Applicants and Owners separately:univ* AND Mainz. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1203
R1 and R1* are selected from hydrogen, C1-7alkyl, hydroxy or C1-7alkyoxy;
R2 and R2* are selected from C1-7alkyl, hydroxyl-C1-7alkyl and C1-7alkyl substituted by oxo;
R3 is hydrogen or hydroxyl;
R4 is hydrogen or hydroxyl;
R4* is hydrogen;
R5 is hydrogen or hydroxyl;
R5* is hydrogen;
R6 is hydrogen or hydroxyl;
R6* is hydrogen;
R7 is C1-7alkyl;
R7* is hydrogen;
R8 is C1-7alkyl;
R8* is C1-7alkyl;
R9 is C1-7alkyl or hydroxyl- C1-7alkyl;
R9* is hydrogen;
R10* is hydroxy;
R12 is hydroxyl;
R13 is C1-7alkyl; and
R14 is hydrogen or hydroxyl;or one or more of the following moieties may also combine to give the respective meanings:
R2* and R12 together form a double bond;
R1* and R2* together form a double bond;
R3* and R4* together form a double bond;
R5* and R6* together form a double bond;
R11 and R12 together form double bond;
R5 and R12 together form a double bond;
R1 and R1* together form oxo;
R3 and R3* together form oxo;
R5 and R5* together form oxo;
R6 and R6* together form oxo;
or R1 and R3 together may also form a moiety of the formula where the ends of the bonds marked with an asterisk (*) bind at the position of R1 (upper asterisk) and R3 (lower asterisk), respectively; or R1, R1* and R2 together form a moiety of the formula where the ends of the bonds marked with an asterisk (*) bind at the position of R1 and R1* (upper asterisk) and R2 (lower asterisk), respectively; or R1 and R2 together form a moiety of the formula where the ends of the bonds marked with an asterisk (*) bind at the position of R1 (upper asterisk) and R2 (lower asterisk); where any double bonds present (including those of oxo) are isolated or conjugated, or both types are present; or a pharmaceutically acceptable salt, hydrate or other solvate thereof."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["According to claim 1 or claim 3 for the use mentioned there, or for the use according to claim 2, a compound of the formula I, or an extract comprising a compound of the formula I R1* and R2* together form a double bond; R3* and R4* together form a double bond R5* and R6* together form a double bond, or each of them is hydrogen or one is hydroxyl, the other hydrogen; and R11 and R12 together form a double bond; while the other moieties are as defined in claim 1 or claim 3, excluding those definitions of these other moieties where pairs of such substituents form =O, =S, =NH or =NR'\" or double bonds or carbocyclic rings; or wherein R1 and R3 together form a moiety of the formula where the ends of the bonds marked with an asterisk (*) bind at the position of R1 (upper asterisk) and R3 (lower asterisk), respectively; R1* and R2* together form a double bond; R3* and R4* together form a double bond R5* and R6* together form a double bond; and R11 and R12 together form a double bond; while the other moieties are as defined in claim 1 or claim 3, excluding those definitions of these other moieties where pairs of such substituents form =O, =S, =NH or =NR\"' or double bonds or carbocyclic rings; or wherein or R1, R1* and R2 together form a moiety of the formula where the ends of the bonds marked with an asterisk (*) bind at the position of R1 and R1* (upper asterisk) and R2 (lower asterisk), respectively; R3 and R3* together form oxo; R4* and R11 together form a double bond; and R5* and R12 together form a double bond; while the other moieties are as defined in claim 1 or claim 3, excluding those definitions of these other moieties where pairs of such substituents form =O, =S, =NH or =NR\"' or double bonds or carbocyclic rings; or wherein or R1, R1* and R2 together form a moiety of the formula where the ends of the bonds marked with an asterisk (*) bind at the position of R1 and R1* (upper asterisk) and R2 (lower asterisk), respectively; R3* and R4* together form a double bond, or each of them is hydroxy; R5* and R6* together form a double bond; and R11 and R12 together form a double bond; while the other moieties are as defined in claim 1 or claim 3, excluding those definitions of these other moieties where pairs of such substituents form =O, =S, =NH or =NR'\" or double bonds or carbocyclic rings; or wherein R1* and R2* together form a double bond; R3* and R4* together form a double bond R6 and R6* together form oxo, and R11 and R12 together form a double bond; while the other moieties are as defined in claim 1 or claim 3, excluding those definitions of these other moieties where pairs of such substituents form =O, =S, =NH or =NR\"' or double bonds or carbocyclic rings; or wherein or R1 and R2 together form a moiety of the formula where the ends of the bonds marked with an asterisk (*) bind at the position of R1 (upper asterisk) and R2 (lower asterisk); R3 and R3* together form oxo; R4* and R11 together form a double bond; and R5* and R12 together form a double bond; while the other moieties are as defined in claim 1 or claim 3, excluding those definitions of these other moieties where pairs of such substituents form =O, =S, =NH or =NR'\" or double bonds or carbocyclic rings, except that R6 and R6* can also form oxo; or wherein R5 and R5* together form oxo; R6 and R6* form oxo; R1* and R2* together form a double bond; R3* and R4* together form a double bond: R11 and R12 together form a double bond; while the other moieties are as defined in claim 1 or claim 3, excluding those definitions of these other moieties where pairs of such substituents form =O, =S, =NH or =NR\"' or double bonds or carbocyclic rings; or wherein R1* and R2* together form a double bond R3* and R4* together form a double bond; R11 and R12 together form a double bond; while the other moieties are as defined in claim 1 or claim 3, excluding those definitions of these other moieties where pairs of such substituents form =O, =S, =NH or =NR'\" or double bonds or carbocyclic rings; or wherein or R1, R1* and R2* together form a moiety of the formula where the ends of the bonds marked with an asterisk (*) bind at the position of R1 and R1* (upper asterisk) and R2 (lower asterisk), respectively; R3 and R3* together form oxo; R4* and R11 together form a double bond; R5* and R6* together form a double bond, or each of them is hydrogen or one is hydroxyl, the other hydrogen; while the other moieties are as defined in claim 1 or claim 3, excluding those definitions of these other moieties where pairs of such substituents form =O, =S, =NH or =NR'\" or double bonds or carbocyclic rings; or wherein R1 and R1* together form oxo; R3* and R4* together form a double bond; R5* and R6* together form a double bond; and R11 and R12 together form a double bond; while the other moieties are as defined in claim 1 or claim 3, excluding those definitions of these other moieties where pairs of such substituents form =O, =S, =NH or =NR'\" or double bonds or carbocyclic rings; or a pharmaceutically acceptable salt, hydrate or other solvate thereof."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["A compound of the formula I for use according to any one of claims 1 to 4, or an extract comprising said compound, where the compound is selected from one or more compounds selected from the group consisting of those with the formulae and or a pharmaceutically acceptable salt, hydrate or other solvate thereof."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["A lipophilic extract from an Agaricus culture, comprising one or more compounds selected from the group consisting of: and or a pharmaceutically acceptable salt, hydrate or other solvate thereof, respectively."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["One or more compounds selected from the group consisting of the compounds with the formula and or a hydrate or other solvate thereof."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A compound, or a pharmaceutically acceptable salt, hydrate or other solvate thereof, or extract according to any one of claims 1 to 7 for use in the treatment of a disease selected from the group of obesity and/or symptoms of Syndrome X."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The use of a compound, or a pharmaceutically acceptable salt, hydrate or other solvate thereof, or an extract according to any one of claims 1 to 8 in the preparation of a medicament (including a nutraceutical) for use in the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to the modulation of Liver X receptor in a mammal."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["A method of treatment of a disease, disorder or condition that responds to the modulation of Liver X receptor, comprising administering to an individual in need of such treatment a pharmaceutically or nutraceutically effective amount of a compound as shown in any one of claims 1 to 8 or a mixture of compounds of such compounds, as active ingredient, where the compound may be in free form, in the form of a pharmaceutically acceptable salt, a hydrate or other solvate."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 10, where the condition to be treated is selected from the group of obesity and/or symptoms of Syndrome X."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical or nutraceutical formulation comprising a compound, or a pharmaceutically acceptable salt, hydrate or other solvate thereof, or an extract according to any one of claims 1 to 8 and at least one pharmaceutically or nutraceutically acceptable carrier materials."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical of nutraceutical formulation according to claim 12 for use in the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to the modulation of Liver X receptor in a mammal."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical or nutraceutical formulation of claim 12 for use in the prophylactic and/or therapeutic treatment of obesity and/or symptoms of Syndrome X."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The use of a compound, or a pharmaceutically acceptable salt, hydrate or other solvate thereof, or an extract according to any one of claims 1 to 8 in the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to the modulation of Liver X receptor in a mammal."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["A process for the preparation of a compound of the formula I or an extract according to any one of claims 1 to 8, comprising extracting and optionally further enriching up to isolating them from mushroom or mushroom part (especially liquid (more especially mycelial) cultures with a non-polar or weakly polar solvent."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The process according to claim 16, where the polarity of the non-polar or weekly polar solvent is defined by an ET(30) value of 56 kcal/mol or lower, preferably 52 Kcal/mol or lower."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The process according to any one of claims 16 and 17, where the mushroom is from the genus Agaricus and, in an 5.8S/ITS nrDNA sequence, comprises a subsequence (ITS1 nrDNA) having a \"Similarity\" with